Evidence map›Paper›PMID 40775344›Full record

ArticleJournal of orthopaedic surgery and research2025

SIRPA, BTN3A1, and TDO2 in osteosarcoma: a prognostic triad with therapeutic implications from integrated genomic and pharmacogenomic data.

Han-Jing Zhang, Zhi-Jun Yang, Wen Huang, Dan Chen, Jie Xiang, Wen-Kang Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Han-Jing ZhangDepartment of Orthopaedics, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Zhi-Jun YangDepartment of Orthopaedics, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Wen HuangDepartment of Orthopaedics, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Dan ChenDepartment of Orthopaedics, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Jie XiangDepartment of Orthopaedics, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Wen-Kang ChenDepartment of Orthopaedics, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China. 1152917781@qq.com.

Funding

Science and Technology Program of Hunan Province 2022JJ40391
6 · The paper itself

Abstract

The limited understanding of the prognostic implications of immune checkpoint molecules in osteosarcoma (OS) poses significant challenges for improving patient outcomes. There is a gap in the identification of reliable biomarkers that can predict treatment response and prognosis in OS patients. This study focused on investigating the prognostic value of immune checkpoints, specifically BTN3A1, SIRPA, and TDO2, using data from the TARGET database and clinical follow-up data from our hospitals. By conducting univariate Cox regression and least absolute shrinkage and selection operator (LASSO) analyses, we identified these immune checkpoints as significant prognostic indicators. A three-immune-checkpoint genetic prognostic risk model was developed, which demonstrated different prognostic implications across different clinical subgroups. Drug sensitivity analysis revealed that BTN3A1, SIRPA, and TDO2 were correlated with the efficacy of several antineoplastic agents, including hydroxyurea and docetaxel. Validation in our clinical cohort highlighted the significant prognostic value of SIRPA, suggesting its potential as a target for immunotherapy. These findings established a framework for using immune checkpoints as prognostic biomarkers, highlighting their important role in enhancing personalized treatment strategies for OS patients.

Indexed as

Bone NeoplasmsOsteosarcomaAdolescentAdultAntineoplastic AgentsBiomarkers, TumorFemaleGenomicsHumansMalePharmacogeneticsPrognosisYoung AdultAntineoplastic AgentsBiomarkers, TumorImmune checkpointsImmune therapyOsteosarcomaPrognosisSIRPA

Identifiers

PMID40775344
PMCPMC12329987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.